Analysis of the dinucleotide repeat polymorphism in the epidermal growth factor receptor (EGFR) gene in head and neck cancer patients
Open Access
- 13 April 2005
- journal article
- research article
- Published by Elsevier in Annals of Oncology
- Vol. 16 (6) , 934-941
- https://doi.org/10.1093/annonc/mdi189
Abstract
Background:: Epidermal growth factor receptor (EGFR) overexpression is associated with poor prognosis in head and neck cancer. The first intron of EGFR gene is polymorphic (9–23 CA repeats) and transcription declines when the number of repeats increases. Patients and methods:: EGFR polymorphism (fluorescent genotyping) and expression (ligand-binding assay) were analyzed in tumors and normal tissues from 112 patients (100 men, 12 women; mean age 60 years). Results:: The number of CA repeats varied from 15 to 22. Allelic distribution was trimodal (predominance of 16, 20 and 18 CA repeats). EGFR concentrations were significantly higher (P=0.02) in homozygous tumors as compared with heterozygous. Considering homozygous tumors, or classifying genotypes as short/long/intermediary (two alleles P=0.047). Tumoral EGFR expression, performance status (WHO criteria) and node involvement were independent predictors of specific survival (P Conclusions:: Intron 1 EGFR polymorphism may be implicated in the regulation of EGFR expression in head and neck tumors.Keywords
This publication has 20 references indexed in Scilit:
- Pharmacological background of EGFR targetingAnnals of Oncology, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Use of the Humanized Anti-Epidermal Growth Factor Receptor Monoclonal Antibody h-R3 in Combination With Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer PatientsJournal of Clinical Oncology, 2004
- Targeting the Epidermal Growth Factor Receptor: An Important Incremental Step in the Battle Against Colorectal CancerJournal of Clinical Oncology, 2004
- Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and NeckJournal of Clinical Oncology, 2004
- The role of epidermal growth factor receptor in head and neck squamous cell carcinomaCurrent Oncology Reports, 2003
- Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (‘Iressa’)British Journal of Cancer, 2002
- The EGFR family and its ligands in human cancerEuropean Journal Of Cancer, 2001
- A multifactorial approach including tumoural epidermal growth factor receptor, p53, thymidylate synthase and dihydropyrimidine dehydrogenase to predict treatment outcome in head and neck cancer patients receiving 5-fluorouracilBritish Journal of Cancer, 1999
- Interactions between the promoter and first intron are involved in transcriptional control of alpha 1(I) collagen gene expression.Molecular and Cellular Biology, 1988